Progress in understanding the genetic basis and pathophysiology of spinal muscular atrophy (SMA), along with continuous efforts in finding a way to increase survival motor neuron (SMN) protein levels have resulted in several strategies that have been proposed as potential directions for efficient drug development. Here we provide an overview on the current status of the following approaches: 1) activation of SMN2 gene and increasing full length SMN2 transcript level, 2) modulating SMN2 splicing, 3) stabilizing SMN mRNA and SMN protein, 4) development of neurotrophic, neuroprotective and anabolic compounds and 5) stem cell and gene therapy. The new preclinical advances warrant a cautious optimism for emergence of an effective treatment in the very near future.
INTRODUCTION
Spinal muscular atrophy (SMA) is the second most common autosomal recessive disorder and one of the leading known genetic causes of infant mortality. It is a neuromuscular disorder of childhood and young adults with an incidence of at least 1/10000 live births [1] . SMA is characterized by a progressive denervation of skeletal muscles, presumably due to the loss of anterior horn cells, and consequently symmetrical hypotonia, muscle weakness, atrophy and paralysis of varying severity [2] [3] [4] [5] [6] . SMA is clinically classified into four types according to the age at onset and disease severity. In SMA type I, or Werdnig-Hoffmann disease, onset is before 9 months of age and affected infants never sit unaided. Death occurs within the first two years, most commonly due to respiratory failure. SMA type II is defined by onset of symptoms between 3 and 15 months, with less severe symptoms than seen in SMA type I patients. Affected children are able to sit unaided, but they are wheelchair-bound and most survive to the 2nd or 3rd decade [7] .
In SMA type III, or Kugelberg-Welander disease, onset is from 4-15 years, children walk unaided, and due to the slow progression of the muscle weakness, they live into adulthood [8] . SMA type IV is a rare, mild form of the disease, with onset after 30 years of age and normal life expectancy [9] . In most developed countries, the diagnosis is based on clinical features and DNA testing (genotyping) in nearly all cases.
Sometimes, the diagnosis is also confirmed by muscle biopsy, electromyography and MRI of the spine.
The underlying genetic defect is on the [12] [13] [14] . However, a higher number of SMN2 copies will generate more than 10% of FL-SMN protein and this will lead to less severe SMA types [15] [16] [17] [18] [19] .
THERAPEUTIC STRATEGIES FOR SMA
A better understanding of pathogenesis and huge preclinical progress are leading to new ideas for SMA therapeutic strategies.
The current main therapeutic strategies are:
1) activation of the SMN2 gene and increasing full length SMN2 transcript level, 2) modulation of SMN2 splicing, 3) stabilization of SMN mRNA and SMN protein, 4) the use of neurotrophic, neuroprotective and anabolic compounds [7, 20] , 5) stem cell and gene therapy. Supportive care to prevent and manage the secondary effects of muscle atrophy is still the basis for treatment of SMA, so the progress in multidisciplinary clinical care should also be developed and nourished [21] [22] [23] .
1. Compounds that activate SMN2 gene and increase full length SMN2 transcript level
Both SMN genes are regulated by a promoter that is almost identical [14, 24] in sequence and activity. Besides cAMP binding protein, Sp family of proteins and interferon regulatory factor [25, 26] , SMN promoter activity is also modulated by histone deacetylase (HDAC) 1 and 2 proteins. Once the core histone NH2-terminus is acetylated, relaxation of corresponding chromatin region enables it to be more transcriptionally active [7, 27, 28] [29] .
Unfortunately, studies indicate that the short half-life of sodium butyrate in human serum does not recommend its use in clinical trials [30] .
A derivative of sodium butyrate -sodium-4-phenyl-butyrate, also known as phenylbutyrate (PB), was also shown to increase SMN transcript expression, SMN protein and gem counts in fibroblast cells derived from SMA patients [31, 32] . It has a well-known pharmacokinetic and safety profile and good penetration into the central nervous system, and so appeared to be a promising candidate for the treatment of SMA. In a small uncontrolled trial an improvement of motor function in 10 SMA type II patients was found after nine weeks of treatment with oral PB, with no apparent major side effects [33] . However, a placebo-controlled trial of intermittent treatment over 13 weeks suggested that there was no improvement in functional scores under the conditions used [34, 35] . A phase I/II study initiated by the US Valproic acid (VPA) or 2 -propylpentanoic acid is the most studied HDAC inhibitor and neurotrophic factor in SMA treatment. It is widely used in the treatment of epilepsy and bipolar disorders [40] . Unlike other HDAC inhibitors, VPA has the advantage of a long half-life of up to 8-10 hours. A few in vitro studies proposed VPA as a promising drug for SMA treatment due to its effect on increasing FL-SMN2 mRNA and protein levels in skin fibroblasts from type I SMA patients [41, 42] . As expected, a stronger response was obtained when low doses of VPA (0.5-5µM)
were administrated on fibroblast lines in SMA patients with more than two SMN2 copies [41] .
In vitro and also in vivo studies [43] have encouraged the opening of VPA clinical trials.
In some patients VPA improved the clinical condition together with an increased SMN protein level and improvement in muscle strength and function; however, in some patients it had no effect or even caused worsening of symptoms [44] [45] [46] Some polyphenolic botanical compounds have been shown to provide benefit in varied genetic diseases [65] . In transient reporter assays, curcumin was shown to increase exon 7 inclusion of SMN2. Full-length SMN mRNA and protein was increased in SMA patient fibroblasts, as well as the formation of SMN-containing nuclear gems [66] . These compounds appear to up-regulate some genes encoding serine/arginine-rich (SR) proteins, which are essential in splicing processes [67] , so this may explain the alternative splicing effects on SMN2 exon 7. Importantly, there is evidence that several polyphenolic compounds can pass the blood brain barrier, which is one of the challenging factors for developing drugs to target motor neurons [65] .
Two studies based on mouse models reported that physical exercise can affect SMN2 splicing regulation, either by modifying the expression pattern of pre-mRNA splicing factors in motoneurons [68] or through the NMDA-receptor activity modulation [69] . [86] . There are also studies indicating that the SMN protein is degraded by the ubiquitin-proteasome system and that drugs that inhibit this pathway increase SMN protein levels in patient-derived fibroblasts [86, 87] Creatine increases muscle mass and strength through its role as an energy shuttle between mitochondria and working musculature, and it could also have neuroprotective effects [96] [97] [98] . In a double-blind randomized placebocontrolled trial in 55 patients with SMA type II and III, unfortunately there was no evidence for a therapeutic effect of oral creatine after six months of treatment [99] .
Interestingly, in-vivo
Gabapentin, an excitatory amino acid neurotransmitter, is another compound with neuroprotective effects due to its antiglutamate action [90] [91] [92] [93] [94] [95] [96] [97] [98] [99] [100] [101] . From one large randomized unblinded and uncontrolled trial with gabapentin in 120 patients with SMA type II and III it was not possible to draw conclusions regarding the efficacy of gabapentin [90] . In the randomized controlled trial in adult patients of 21 years or older with SMA type II and III there was no evidence for significant efficacy of twelve months treatment with oral gabapentin [102] . 
Neurotrophic compounds
Cardiotrophin-1 is a cytokine from interleukin-6 family, with known beneficial effects on survival of motor neurons during the embryonic period [105] . A preclinical study in SMA mice
showed that cardiotrophin-1 delivery to SMA mutant mice resulted in protection of proximal and distal motoneurons, which was present even in postnatal period [106] . In this study, cardiotrophin-1 was delivered by intramuscular injection with an adenoviral vector expressing cardiotrophin-1 and it was able to improve survival and delay the motor defect in SMAΔ7 mice in neurons even at low doses. It provided good evidence that neurotrophic factors deserve further study as potential drugs in SMA [20] .
Thyrotropin releasing hormone (TRH) has
been shown to have a neurotrophic effect on spinal motor neurons of SMA patients [107] .
A small double-blind randomized placebo- [7] . Some interesting and promising data show that these stem cell-derived motor neurons can grow axons and form neuromuscular junctions in preclinical experiments [123, 124] .
Transplantation of differentiated ESCs into rat spinal cord after induced motor neuron injury also shows promising results: cells survived, but also produced axons that were able to grow into the ventral root [125, 126] .
The motor neuron function improvement and survival of SMA mice led to the conclusion that neural stem cell transplantation has positive effects on SMA disease phenotype [127] . The They also reported that IV injection in a male cynomolgus macaque at PND01 of scAAV9-GFP successfully transfected dorsal root ganglia and motor neurons, demonstrating that it has the potential to cross the blood-brain barrier in
primates.
An alternative RNA strategy for preventing SMN2 exon 7 from skipping is to use a trans-splicing system. It has been recently introduced in therapeutic assays for cystic fibrosis [143] and Alzheimer's disease [144] . This 
Other approaches
The base of treatment in SMA is still supportive care, which requires multidisciplinary medical care [21] . Due to intensive supportive care, such as ventilation, the use of mechanical insufflation-exsufflation device and tube feeding, the survival of patients with SMA type I has significantly increased in recent years [22] . with the multidisciplinary care of these patients [124] .
Since forced exercise was found to be of benefit in ALS mouse models [147, 148] it was recently studied in SMA mice. Type II SMA mice developed by Hsieh-Li et al. [149] were used in the interesting study of Grondard et al. [68] .
The mice were subjected to a training protocol of forced run on a wheel or no training. It is ethically debatable whether it is desirable to treat patients with SMA type I with a drug that has an effect on survival, but does not appear to improve motor function and has no effect on achieving motor milestones such as rolling, sitting, standing or walking. Recently, arguments for and arguments against were described [93] [94] [95] .
Altogether, there has been a huge progress in new approaches and development of a wider range of animal models for SMA, which provides cautious optimism that effective treatment for SMA will eventually emerge [159] .
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